BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld MedTech
Home
» St. Jude, Thoratec show a lot of Heart in transaction: St. Jude shows it has 'heart' with proposed $3.4B Thoratec acquisition
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
St. Jude, Thoratec show a lot of Heart in transaction: St. Jude shows it has 'heart' with proposed $3.4B Thoratec acquisition
July 23, 2015
By
Omar Ford
No Comments
St. Jude Medical (NYSE:STJ) (St. Paul, Minn.) said that it has agreed to acquire Thoratec (NASDAQ:THOR) (Pleasanton, Calif.) for $63.50 per share in a cash transaction valued at about $3.4 billion.
BioWorld MedTech